M
ENLO PARK, Calif.--Deltagen announced that it has completed a $22.5 million round of financing that was led by Boston Millennia Partners and included investments by the Sprout Group, Baccharis Capital, Crossroads, and Lombard Odier & Cie. The proceeds of the offering will enable the company to advance several new drug target discovery programs as well as finalize and fully commercialize its DeltaBase product, a database with information about mammalian genes specifically relevant to small molecule drug discovery.
